Videos

Without an established treatment algorithm, therapy selection for VMS-associated sleep disturbance rests on comorbidities, symptom timing, safety, and iterative reassessment through shared decision-making.

Neurokinin receptor antagonists improve sleep in addition to VMS, but the magnitude of benefit, the quality of the measures, and the mechanism differ meaningfully by agent and from hormone therapy.

Arina Chesnokova, MD, MPH, discusses rising hormone therapy prescribing despite contraindications, when to refer, and how lost AHRQ funding slowed her work.

Arina Chesnokova, MD, MPH, describes an EHR-based algorithm designed to help primary care clinicians prescribe menopause therapy safely and know when to refer.

Arina Chesnokova, MD, MPH, discusses EHR data showing menopause is rarely coded in primary care, with lower rates among racially minoritized and publicly insured women.

Effective planning begins with grading VMS severity, characterizing the sleep complaint, and confirming hormone therapy candidacy, while recognizing that most sleep evidence derives from trials designed to treat hot flashes.

Limited visit time, minimal sleep medicine training, and widespread self-medication leave many women with menopause-related sleep disturbance underdiagnosed or treated with poorly supported agents.

One question at every visit could prevent strokes in atrial fibrillation, says Geoffrey Barnes, MD, who also previews investigational anticoagulants.

Annual injections, every-4-month dosing, and a once-monthly pill could reshape HIV prevention. Yet the faculty agree the most powerful step remains asking every patient about sexual health and PrEP.

Linda Bradley, MD, explains why blind endometrial sampling may miss focal uterine pathology and when persistent abnormal bleeding should prompt hysteroscopy or referral.

Pauline M. Maki, PhD, discusses how the boxed-warning removal for hormone therapy and an expanding class of neurokinin-targeted therapies broaden options, and shares her key takeaway from OPTION-VMS.

Nearly half of menopausal sleep disruption tracks with nighttime hot flashes, while the remainder appears independent, making nocturnal fragmentation a distinct clinical target rather than a secondary effect.

Sleep disturbance is often the most bothersome symptom of the menopause transition, yet it frequently goes unreported unless clinicians ask directly about sleep quality and daytime fatigue.

Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, discusses barriers and primary care interventions.

Cheryl Cox Kinney, MD, identifies VMS red flags that warrant further evaluation, including fever, weight loss, lymphadenopathy, and persistent symptoms.

TMS 2026: Approximately 21% of women initiated systemic HT after menopause, with substantial declines in treatment persistence during the first 2 years.

TMS 2026: JoAnn Pinkerton, MD, discusses elinzanetant's onset of VMS relief, common adverse effects, and treatment expectations for primary care physicians.

Long-acting PrEP succeeds only with the right infrastructure. The faculty detail the benefits, nursing, and quality teams a clinic needs, and the staffing and reimbursement pharmacies require to furnish PrEP sustainably.

Fear that a pill bottle signals HIV or promiscuity still keeps patients from PrEP. The faculty discuss how long-acting options may ease stigma and adherence anxiety, and what acceptability data show so far.

A single-injection crossover study suggested participants preferred cabotegravir over lenacapavir. The faculty explain why they view the findings as a counseling aid rather than a reason to favor one agent.

TMS 2026: Stephanie Faubion, MD, on how to identify overlooked menopause symptoms and guide hormonal or nonhormonal treatment decisions in primary care settings.

Pauline M. Maki, PhD, reviews the real-world safety experience with fezolinetant (Veozah) in OPTION-VMS and the hepatic monitoring, dosing, and onset details clinicians need when prescribing.

TMS 2026: Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, and anxiety symptoms.

Long-acting cabotegravir and lenacapavir both deliver near-complete protection. The faculty compare dosing schedules, drug interactions, and injection site reactions, and share techniques that make injections easier to tolerate.

Four approved PrEP options now span daily pills and long-acting injections. The faculty review how each agent works and where daily oral PrEP succeeds or falls short in practice.

Pauline M. Maki, PhD, explains how actigraphy objectively captures menopause-related sleep disruption and reviews OPTION-VMS findings on wakefulness after sleep onset with fezolinetant and SSRIs/SNRIs.

Treatment does not end with a prescription. The panel closes by examining who owns follow-up care, and why caregivers remain the true cornerstone of managing Alzheimer's agitation over time.

When first-line therapy falls short, the decision to augment or switch is rarely straightforward. The panel examines that decision-making process alongside neurology's evolving role in managing agitation.

Jovan Milosavljevic, MD, an endocrinologist at Montefiore Einstein, explains what is driving CGM growth, which patients to consider, and what continuous data adds.

Every clinician can prescribe or refer for PrEP. The faculty outline the education, team structures, and community outreach that build prescriber confidence, and explain why HIV prevention still matters in the treatment era.